

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of P. Isakson et al.

Art Unit TBA

Serial No. TBA

Filed HEREWITH

Confirmation No. TBA

For TREATMENT OF INFLAMMATION AND INFLAMMATION-RELATED DISORDERS  
WITH A COMBINATION OF A CYCLOOXYGENASE-2 INHIBITORS AND A  
LEUKOTRIENE B<sub>4</sub> RECEPTOR ANTAGONIST

Examiner TBA

H5A  
B  
5/16/00

January 3, 2002

PRELIMINARY AMENDMENT A

Prior to calculating the filing fee in this matter, please enter the following amendments in the above-referenced application.

IN THE RELATED CASE:

Please replace the paragraph on Page 1, lines 7-8 with the following:

--This is a continuation of US Application Serial No. 08/661,641, filed June 11, 1996 which application is a continuation-in-part of US Application Serial No. 08/489,415, filed June 12, 1995.--

IN THE SPECIFICATION:

Please replace the paragraph on page 5, lines 6-12 with the following:

--In addition, the invention describes a combination comprising a therapeutically-effective amount of a leukotriene B<sub>4</sub> receptor antagonist and a cyclooxygenase-2 inhibitor selected from Taisho NS-398 (Methanesulfonamide, N-[2-(cyclohexyloxy)-4-nitrophenyl]), meloxicam (2H-1,2-Benzothiazine-3-carboxamide, 4-hydroxy-2-methyl-N-(5-methyl-2-thiazolyl)-, 1,1-dioxide), flosulide (Methanesulfonamide, N-[6-(2,4-difluorophenoxy)-2,3-dihydro-1-oxo-1H-inden-5-yl]), Merck MK-966 (2(5H)-Furanone, 4-[4-